SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
30. August 2023 07:00 ET
|
SparingVision
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12. Juli 2023 07:00 ET
|
SparingVision
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
09. Dezember 2021 07:00 ET
|
SparingVision
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19. März 2021 08:00 ET
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 07:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 01:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...